NEW YORK (GenomeWeb) – Abbott has inked deals with Celgene and Agios Pharmaceuticals to develop and commercialize PCR-based companion diagnostic tests that will identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia.